Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Benzinga10-18

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Alumis’ lead drug candidate, ESK-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476829844?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dhcNQjHv6E4p246dydUpYw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7b0670e7da8c4cb8c5e36ff60eee0742","is_english":true,"pubTime":"2024-10-18 02:32","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476829844","market":"us","top_or_hot":-1,"title":"Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside","media":"Benzinga","content":"<div>\n<p>HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.\nAlumis’ lead drug candidate, ESK-...</p>\n\n<a href=\"https://finance.yahoo.com/news/alumis-investigational-lead-candidate-supports-183211063.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 02:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/alumis-investigational-lead-candidate-supports-183211063.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.\nAlumis’ lead drug candidate, ESK-...</p>\n\n<a href=\"https://finance.yahoo.com/news/alumis-investigational-lead-candidate-supports-183211063.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/alumis-investigational-lead-candidate-supports-183211063.html","article_id":"2476829844","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dhcNQjHv6E4p246dydUpYw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7b0670e7da8c4cb8c5e36ff60eee0742"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476829844","pubTimestamp":1729189931,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"HC Wainwright has initiated coverage on Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2  inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis  and in Phase 2 trials for systemic lupus erythematosus . HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30.Also Read: Newly-Listed Psoriasis-Focused Alumis Attracts Analysts’ Attention With Promising Lead Program And Modest Valuation.According to HC Wainwright, ESK-001 boasts the highest selectivity within the TYK2 inhibitor space, outperforming Bristol Myers Squibb & Co’s  approved drug, Sotyktu  and Takeda Pharmaceutical Co Ltd’s  Phase 3 candidate, TAK-279.While Sotyktu currently leads the TYK2 market, HC Wainwright emphasizes that clinical data for ESK-001 suggest a significantly superior profile, which could drive substantial growth in the TYK2 ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BMY":"施贵宝","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4581":"高盛持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","TAK":"武田制药","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","MYE":"Myers Industries Inc","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4126":"金属与玻璃容器","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4532":"文艺复兴科技持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4534":"瑞士信贷持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4007":"制药","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4077":"互动媒体与服务","SLE":"Super League Gaming Inc.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","BK4588":"碎股","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","ALMS":"Alumis Inc.","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC"},"translate_title":"Alumis的主要研究候选药物比百时美施贵宝的商业化药物具有更好的知名度，分析师预计股价上涨170%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1,"SLE":1,"MYE":1,"BMY":1,"TAK":0.9},"content_text":"HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.\nAlumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis (PsO) and in Phase 2 trials for systemic lupus erythematosus (SLE). HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30.\nAlso Read: Newly-Listed Psoriasis-Focused Alumis Attracts Analysts’ Attention With Promising Lead Program And Modest Valuation.\nAccording to HC Wainwright, ESK-001 boasts the highest selectivity within the TYK2 inhibitor space, outperforming Bristol Myers Squibb & Co’s (NYSE:BMY) approved drug, Sotyktu (deucravacitinib) and Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Phase 3 candidate, TAK-279.\nWhile Sotyktu currently leads the TYK2 market, HC Wainwright emphasizes that clinical data for ESK-001 suggest a significantly superior profile, which could drive substantial growth in the TYK2 class and expand its market share in major indications.\nThe analyst suggests that ESK-001’s strong efficacy has the potential to drive significant growth in the TYK2 market, boosting market share for the class in major indications.\nESK-001’s mechanism of action (MOA) in psoriasis is de-risked by the approval of Sotyktu, the first-generation oral TYK2 inhibitor already approved for this use.\nAdditionally, the 28-week Phase 2 open-label extension (OLE) data for ESK-001 shows favorable comparisons to Sotyktu.\nHC Wainwright models peak sales of around $1.9 billion for ESK-001 in plaque psoriasis and ~$2.0 billion for ESK-001 in systemic lupus erythematosus.\nAlthough Sotyktu’s patents start expiring in 2026, it is estimated that generic versions may not hit the market until late 2033. HC Wainwright anticipates that ESK-001 could easily outperform Sotyktu in the market, given its significant advantages against another drug in the same TYK2 inhibitor class.\nPrice Action: ALMS stock is down 2.68% at $10.89 at the last check on Thursday.\nRead Next:\n\nWhy Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476829844"}